Share
.webp)
.webp)
.webp)
.webp)
Keeley Wettan
Gilead Sciences, Inc. has appointed Keeley Wettan as Executive Vice President, General Counsel, and Legal & Compliance.
In this role, she joins the company’s senior leadership team and will report directly to Chairman and Chief Executive Officer Daniel O’Day. Her appointment reflects Gilead’s continued focus on strong legal governance and compliance as the company advances its global scientific and commercial priorities.
Ms. Wettan brings more than 14 years of experience at Gilead, during which she has held a series of increasingly senior legal leadership roles. Most recently, she served as Senior Vice President leading the Global Legal Business Partners team, where she played a critical role in advising on complex legal, regulatory, and business matters across Gilead’s global operations. Earlier in her tenure, she led the Litigation and Government Investigations team, as well as the Corporate Governance and Strategic Transactions function, gaining broad exposure to enterprise-wide legal strategy and risk management.
Throughout her career at Gilead, Ms. Wettan has been instrumental in supporting the launch of several transformative medicines. Notably, she played a key role in the recent launch of lenacapavir, a first-in-class, twice-yearly HIV prevention medicine that represents a major advancement in public health. In addition to her corporate responsibilities, she currently serves as Chair of the Board of the Gilead Foundation, reinforcing the company’s commitment to social impact and community engagement.
Prior to joining Gilead, Ms. Wettan practiced law at Simpson Thacher & Bartlett in New York City, where her work focused on general litigation and government investigations. She earned her Juris Doctor degree from the University of California, Berkeley.
